Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hematologic cancer
Biotech
GSK pens $50M pact to join Big Pharma peers in emerging modality
GSK will work with LTZ on myeloid cell engagers, a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
Nick Paul Taylor
Nov 19, 2025 4:40am
IGM cuts head count 22%, stops blood cancer work to stretch cash
Dec 6, 2023 10:11am
Caribou heads 'where the puck is going' with cell therapy plan
Jun 6, 2023 2:25pm
Precision to aim an off-the-shelf CAR-T at patients who relapse
May 31, 2023 10:58am
J&J, flush with blood cancer assets, cuts one from the pipeline
Oct 18, 2022 10:50am
Galecto links blood cancer prospect to reduced fibrosis
Sep 29, 2022 9:20am
